These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21178026)

  • 1. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
    Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM
    AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium.
    Tamada T; Ito K; Yamamoto A; Sone T; Kanki A; Tanaka F; Higashi H
    AJR Am J Roentgenol; 2011 Apr; 196(4):824-30. PubMed ID: 21427331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
    Davenport MS; Caoili EM; Kaza RK; Hussain HK
    Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.
    Pietryga JA; Burke LM; Marin D; Jaffe TA; Bashir MR
    Radiology; 2014 May; 271(2):426-34. PubMed ID: 24475864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fat-suppressed dynamic and delayed gadolinium-enhanced volumetric interpolated breath-hold magnetic resonance imaging of cholangiocarcinoma.
    Leyendecker JR; Gakhal M; Elsayes KM; McDermott R; Narra VR; Brown JJ
    J Comput Assist Tomogr; 2008; 32(2):178-84. PubMed ID: 18379298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.
    Goshima S; Kanematsu M; Kondo H; Watanabe H; Kawada H; Moriyama N; Bae KT
    AJR Am J Roentgenol; 2013 Sep; 201(3):578-82. PubMed ID: 23971449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory-triggered three-dimensional T2-weighted MR cholangiography after injection of gadoxetate disodium: is it still reliable?
    Ringe KI; Gupta RT; Brady CM; Massey CM; Hahn A; Galanski M; Merkle EM; Lotz J
    Radiology; 2010 May; 255(2):451-8. PubMed ID: 20413758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
    Choi JY; Kim MJ; Park YN; Lee JM; Yoo SK; Rha SY; Seok JY
    AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging.
    Onishi H; Theisen D; Dietrich O; Reiser MF; Zech CJ
    J Magn Reson Imaging; 2014 Jan; 39(1):42-50. PubMed ID: 24339365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study.
    Cho SH; Kang UR; Kim JD; Han YS; Choi DL
    Eur J Radiol; 2011 Nov; 80(2):e195-200. PubMed ID: 21908121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
    Davenport MS; Viglianti BL; Al-Hawary MM; Caoili EM; Kaza RK; Liu PS; Maturen KE; Chenevert TL; Hussain HK
    Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?
    Bashir MR; Husarik DB; Ziemlewicz TJ; Gupta RT; Boll DT; Merkle EM
    J Magn Reson Imaging; 2012 Mar; 35(3):611-6. PubMed ID: 22034383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
    Vernuccio F; Cannella R; Gozzo C; Greco V; Midiri M; Furlan A; Tang A; Brancatelli G
    Abdom Radiol (NY); 2020 Aug; 45(8):2409-2417. PubMed ID: 32435849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.